NEW YORK, March 28, 2011 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $249,810 to Yuma Therapeutics Corporation (Yuma) to develop small molecules to treat Alzheimer's disease.
The award will fund work to develop Yuma's innovative disease-modifying pharmaceutical compounds that target neurofibrillary tangles resulting from abnormal forms of the protein tau, which represents a promising new approach with potential to affect disease progression in Alzheimer's disease.
"We are excited to support Yuma Therapeutics innovative program in this area," said Howard Fillit, M.D., executive director of the ADDF. "Small molecule therapeutics targeting the tau pathway could result in a disease-modifying therapy for Alzheimer's disease."
"We are honored to be selected for this peer-reviewed grant, which recognizes the promise of Yuma's approach to generating novel Alzheimer's disease therapies," said Yukari Y. Perrella, founder and president of Yuma. "We look forward to interacting with the ADDF team."
About the Alzheimer's Drug Discovery Foundation (www.AlzDiscovery.org)
The ADDF is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. Since 1998, the ADDF has granted more than $45 million to fund over 325 Alzheimer's drug discovery and development programs in academic centers and biotechnology companies in 17 countries.
About Yuma Therapeutics Corporation (www.yumatherapeutics.com)
Yuma Therapeutics is a privately held biopharmaceutical company focused on developing novel disease-modifying small molecule drugs to treat neurodegenerative diseases. The Company is developing pharmaceutical compounds that target the tau pathway, a promising new approach to affect the disease progression of Alzheimer's disease.
|SOURCE Alzheimer's Drug Discovery Foundation|
Copyright©2010 PR Newswire.
All rights reserved